Sponsor link https://cdmrp.army.mil/funding/kcrp

Applications submitted to the FY22 KCRP must address one or more of the following Focus Areas:

• Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
• Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
• Develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
• Identify and implement strategies to improve the quality of life and survivorship for patients.
• Identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
• Support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care in alignment with the KCRP Overarching Strategic Goals.

Funding Opportunities - FY22 Kidney Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

 

Concept Award – Letter of Intent due June 23, 2022

All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible

Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

• Emphasis on innovation.
• Funding for clinical trials not allowed.
• Preliminary data not allowed and should not be discussed.
• Blinded review.

• Maximum funding of $100,000 for direct costs (plus indirect costs).
• Maximum period of performance 1 year.

 

Idea Development Award Modified for FY22 – Preproposal due June 2, 2022

Established Investigators: 

Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree.

Early-Career Investigators:

Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency/fellowship or family medical leave) at the time of application submission deadline.

• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• Preliminary data required.
• Innovation and impact are the most important review criteria.
• Funding for clinical trials not allowed.
• Different funding options, based on the scope of research are available with compelling justification. 

• Maximum funding of $675,000 in direct costs (plus indirect costs).

• Period of performance not to exceed 3 years.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Postdoctoral and Clinical Fellowship Award – Letter of Intent due June 23, 2022

Must have completed requirements for a Ph.D. and/or M.D.

Must be in the laboratory or clinical setting where proposed research will be performed.

Must have no more than 4 years of postdoctoral and/or mentored clinical research experience.

Investigators in non-postdoctoral and/or clinical fellow positions are not eligible.

Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers.

• A designated mentor who is an experienced kidney cancer researcher is required.

• Clinical trials are not allowed.

• Maximum funding of $195,000 for direct costs (plus indirect costs).

• Maximum period of performance is 3 years.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Translational Research Partnership Award – Preproposal due June 2, 2022

The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor or equivalent.

The Partnering PI must be at or above the level of Assistant Professor or equivalent.

• Postdoctoral fellows are not eligible to be Partnering PIs. .

• Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

• Supports translational correlative studies.

• Preliminary data are required.

• Clinical trials are not allowed.

• Maximum funding of $750,000 for direct costs (plus indirect costs).

• Maximum period of performance is 3 years.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.